1. Management challenges of recurrent venous thromboembolism in advanced digestive cancers: Case studies and therapeutic strategies.
- Author
-
Doutrelon C, Matray C, Klotz C, Delamarre S, Razafinimanana M, De Charry F, Cournac JM, Jacquier C, Billhot M, and Aletti M
- Subjects
- Humans, Middle Aged, Male, Female, Fatal Outcome, Treatment Outcome, Palliative Care, Disease Progression, Heparin, Low-Molecular-Weight therapeutic use, Risk Factors, Blood Coagulation drug effects, Gastrointestinal Hemorrhage etiology, Gastrointestinal Hemorrhage therapy, Gastrointestinal Hemorrhage drug therapy, Venous Thromboembolism drug therapy, Venous Thromboembolism etiology, Venous Thromboembolism diagnosis, Anticoagulants therapeutic use, Recurrence, Pulmonary Embolism drug therapy, Pulmonary Embolism etiology
- Abstract
Introduction: Venous thromboembolism (VTE) poses a significant challenge in cancer patients, particularly those with advanced malignancies. The management of recurrent VTE is complicated by the need for effective anticoagulation while addressing the underlying cancer progression., Cases: We present two clinical cases from the gastroenterology department at Percy French military hospital involving patients with progressive malignant digestive diseases. Patient 1, a 62-year-old woman, developed recurrent pulmonary embolism despite appropriate anticoagulation with low molecular weight heparin (LMWH). After treatment adjustments, she ultimately succumbed to tumor progression. Patient 2, a 54-year-old man hospitalized for pulmonary embolism, faced upper gastrointestinal bleeding and delayed anticoagulation initiation. Although he showed initial improvement with immunotherapy and stabilization of thrombotic events, he experienced oncological progression and recurrent VTE, leading to palliative care., Discussion: These cases illustrate the difficulties of managing recurrent VTE, even with curative anticoagulation and dose escalation. In case of VTE recurrence, it is essential to investigate for cancer progression and ensure patient adherence to treatment. A comprehensive management strategy should involve both the malignancy and the thrombotic complications., Conclusion: The management of recurrent VTE in cancer patients requires a multidisciplinary approach to evaluate the benefit-risk ratio of anticoagulation adjustments. These clinical cases highlight the necessity for integrated care that addresses both oncological and thrombotic concerns, emphasizing the importance of timely intervention and collaboration among healthcare providers., (Copyright © 2024 Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF